Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGP100 in CPVT
NCT07263139Phase 2Recruiting
- Sponsor
- Agiana Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AGP100 in catecholaminergic polymorphic ventricular tachycardia (CPVT), sponsored by Agiana Pharmaceuticals. Started Jan 2026; status: recruiting.
02
Drugs
AGP100
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on NCT07263139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263139.